Pmv Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Sio Capital Management, LLC has reported a beneficial ownership of 4.94% in PMV Pharmaceuticals, Inc. as of June 30, 2026.
NASDAQ
ArrowMark Colorado Holdings, LLC has reported beneficial ownership of 1,959,579 shares, representing 3.67% of the outstanding common stock of PMV Pharmaceuticals, Inc., as of June 30, 2026.
NASDAQ
Euclidean Capital and affiliated entities report a 4.9% beneficial ownership stake in PMV Pharmaceuticals, Inc.
NASDAQ
Sio Capital Management, LLC has reported a beneficial ownership of 5.77% in PMV Pharmaceuticals, Inc. as of March 31, 2026.
NASDAQ
BML Investment Partners, L.P. has reported a 9.9% beneficial ownership stake in PMV Pharmaceuticals, Inc., holding 5,292,000 shares of common stock.
NASDAQ
Sio Capital Management, LLC has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.98% in PMV Pharmaceuticals, Inc. as of September 30, 2025.
NASDAQ
Tang Capital Management and affiliated entities have reported an 8.9% beneficial ownership stake in PMV Pharmaceuticals, Inc., holding 4,720,357 shares.
NASDAQ
PFM Health Sciences and related entities filed an amended Schedule 13G, reporting zero beneficial ownership in PMV Pharmaceuticals, Inc.
NASDAQ
Sio Capital Management, LLC has reported a 7.19% beneficial ownership stake in PMV Pharmaceuticals, Inc. as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: PFM Health Sciences Discloses 6.4% Stake in PMV Pharmaceuticals
PFM Health Sciences and its affiliated entities have filed an amended Schedule 13G, revealing a 6.4% beneficial ownership in PMV Pharmaceuticals, Inc.
NASDAQ
Sio Capital Management, LLC has reported a 7.19% beneficial ownership stake in PMV Pharmaceuticals, Inc. as of March 31, 2025, according to a recent Schedule 13G filing.
NASDAQ
PFM Health Sciences and its affiliated entities have reported a 5.0% beneficial ownership stake in PMV Pharmaceuticals, Inc., holding 2,598,827 common shares.
NASDAQ
SCHEDULE 13G/A: BML Investment Partners Amends Stake in PMV Pharmaceuticals, Correcting Ownership to 6.7%
BML Investment Partners, L.P. has filed an amended Schedule 13G, correcting its beneficial ownership in PMV Pharmaceuticals, Inc. to 3,466,684 shares, representing 6.7% of the common stock.
NASDAQ
BML Investment Partners, L.P. has filed an amended Schedule 13G, revealing a 6.3% beneficial ownership stake in PMV Pharmaceuticals, Inc.'s common stock as of December 31, 2024.
NASDAQ
Sio Capital Management, LLC has reported a 6.9% beneficial ownership stake in PMV Pharmaceuticals, Inc. as of December 31, 2024, according to a recent Schedule 13G filing.